Citius Pharmaceuticals, Inc.CTXR

Citius Pharmaceuticals, Inc. cleared the FDA’s finish line in early June 2026 for LYMPHIR™, an IL-2 diphtheria toxin fusion protein now in-licensed and marketed by its subsidiary Citius Oncology, giving the company its first marketed product in a decade of clinical pilgrimage. The approval arrives not a moment too soon for a balance sheet that, as of 31 March 2026, held just $4.6 million in cash against $63.5 million in liabilities and a $61.5 million equity stub. (source: CTXR 8-K (2026-06-01), https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm)

What Citius actually sells is a single FDA-approved oncology asset aimed at patients with persistent or recurrent cutaneous T-cell lymphoma, a niche tucked inside a larger pipeline that still lacks late-stage confirmatory data. The company’s 2026-03-31 10-Q shows $1.7 million in revenue for the quarter, a figure that would be unremarkable for a family restaurant and faintly embarrassing for a drug developer with a marketed product. Meanwhile, net cash used in operating activities was $14.3 million for the three months, and inventory crept up by $372,897 even as sales flatlined. (source: CTXR 10-Q (2026-05-15), https://www.sec.gov/Archives/edgar/data/1506251/000121390026057842/ea0290552-10q_citius.htm)

The company’s filings this quarter read like a ledger of survival tactics rather than growth levers. Net loss attributable to parent widened to $11.5 million for the twelve months ending 31 March 2026, operating loss was $32.2 million, and research and development spend was $1.6 million. Diluted weighted average shares outstanding reached 22.4 million, pushing EPS to a loss of $0.95. Cash and equivalents stood at $4.6 million, while total assets were $132.5 million and liabilities $63.5 million. The company’s own SEC submission index shows a dossier stretching back to 2015, a timeline that feels less like a strategic runway and more like a reminder that patience can curdle into dilution. (source: CTXR SEC submissions JSON, https://data.sec.gov/submissions/CIK0001506251.json)

For those hunting for price signals, the company’s stock trades on the OTCQB under CTXR and is tracked on standard retail platforms; no exchange-level data is required by the evidence to hand you levels, ranges, or volume trends. The filing rail provides the operating reality; the market plumbing remains a user choice, not a sourced fact. (source: CTXR SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001506251.json)

Citius also touts Mino-Lok®, a catheter clearance therapy that the company says, based on Phase 2b results from December 2014, is highly effective in salvaging infected catheters; the only public evidence filed this quarter is a product image on the pipeline page and a general statement of belief. No Phase 3 data, no peer-reviewed publication attached to the filing set, and no contractual revenue model disclosed. The gap between the polished slide deck and the 10-Q is now a chasm bordered by inventory and red ink. (source: CTXR Clinical Trials & Publications, https://citiuspharma.com/pipeline/clinical-trials/default.aspx)

The company’s latest S-3 shelf registration filed in May 2026 is the statutory equivalent of a “keep the lights on” document, not a signal of imminent capital deployment. Meanwhile, the 13D/A filed on 4 June 2026 shows a 1.9% beneficial ownership stake, while the company’s own investor email alerts page quietly asks for consent to send updates-because nothing says “shareholder democracy” like a pop-up cookie consent in the corner of a PowerPoint. (source: CTXR S-3 (2026-05-22), https://www.sec.gov/Archives/edgar/data/1506251/000121390026060644/ea0291448-s3_citius.htm; CTXR EFFECT (2026-06-02), https://www.sec.gov/Archives/edgar/data/1506251/999999999526001857/xslEFFECTX01/primary_doc.xml)

The tension sits between the FDA’s green light for LYMPHIR™ and the company’s ability to fund its runway long enough to convert approval into revenue. The board’s recent 13D/A and a shelf registration do not, by themselves, prove capital will arrive, nor do they guarantee operating leverage. Until the company files revenue guidance or a concrete supply or distribution agreement tied to LYMPHIR™, the market remains a spectator to a balance-sheet drama where the hero is still writing IOUs. (source: CTXR SCHEDULE 13D/A (2026-06-04), https://www.sec.gov/Archives/edgar/data/1506251/000121390026065310/xslSCHEDULE_13D_X02/primary_doc.xml)']